The prevalence of diabetes in Nepal has been steadily increasing over the past few years, leading to a rise in demand for anti-diabetes drugs.
Customer preferences: Patients in Nepal tend to prefer traditional medicine over modern medicine, which has limited the growth of the anti-diabetes drugs market. However, with the increasing awareness about the benefits of modern medicine, there has been a shift in customer preferences towards anti-diabetes drugs.
Trends in the market: The anti-diabetes drugs market in Nepal is dominated by multinational pharmaceutical companies. These companies have been introducing new and innovative drugs to the market, which has led to increased competition and lower prices. Additionally, there has been an increase in the availability of generic drugs, which has further increased competition in the market.
Local special circumstances: Nepal is a developing country with limited healthcare infrastructure. This has led to a lack of access to healthcare services in rural areas, which has limited the growth of the anti-diabetes drugs market in these areas. However, the government has been taking steps to improve healthcare infrastructure in the country, which is expected to increase the demand for anti-diabetes drugs.
Underlying macroeconomic factors: Nepal has a growing economy, which has led to an increase in disposable income among the population. This has led to an increase in demand for healthcare services, including anti-diabetes drugs. Additionally, the government has been providing subsidies for healthcare services, which has further increased the affordability of anti-diabetes drugs for the population.In conclusion, the anti-diabetes drugs market in Nepal is expected to continue growing in the coming years, driven by increasing awareness about the benefits of modern medicine and improving healthcare infrastructure in the country. However, the market is likely to face challenges due to the preference for traditional medicine and limited access to healthcare services in rural areas.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
